1.72 USD
+0.04 (+2.38%)
Taking everything into account, SNDL scores 4 out of 10 in our fundamental rating. SNDL was compared to 191 industry peers in the Pharmaceuticals industry. SNDL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SNDL is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
SNDL had negative earnings in the past year.
SNDL had a positive operating cash flow in the past year.
In the past 5 years SNDL always reported negative net income.
In the past 5 years SNDL reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -7.00%, SNDL is in the better half of the industry, outperforming 70.16% of the companies in the same industry.
SNDL has a Return On Equity of -8.39%. This is in the better half of the industry: SNDL outperforms 75.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7% | ||
| ROE | -8.39% | ||
| ROIC | N/A |
ROA(3y)-13.41%
ROA(5y)-27.04%
ROE(3y)-16.09%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 27.03%, SNDL is in line with its industry, outperforming 54.97% of the companies in the same industry.
In the last couple of years the Gross Margin of SNDL has remained more or less at the same level.
SNDL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 27.03% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y38.61%
GM growth 5Y-0.23%
2. Health
2.1 Basic Checks
SNDL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SNDL has about the same amount of shares outstanding.
SNDL has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, SNDL has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.25, we must say that SNDL is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SNDL (1.25) is comparable to the rest of the industry.
The Debt to FCF ratio of SNDL is 2.69, which is a good value as it means it would take SNDL, 2.69 years of fcf income to pay off all of its debts.
SNDL has a better Debt to FCF ratio (2.69) than 91.10% of its industry peers.
SNDL has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of SNDL (0.11) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 2.69 | ||
| Altman-Z | 1.25 |
ROIC/WACCN/A
WACC8.11%
2.3 Liquidity
A Current Ratio of 5.04 indicates that SNDL has no problem at all paying its short term obligations.
With a decent Current ratio value of 5.04, SNDL is doing good in the industry, outperforming 64.92% of the companies in the same industry.
SNDL has a Quick Ratio of 3.54. This indicates that SNDL is financially healthy and has no problem in meeting its short term obligations.
SNDL has a Quick ratio of 3.54. This is comparable to the rest of the industry: SNDL outperforms 58.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.04 | ||
| Quick Ratio | 3.54 |
3. Growth
3.1 Past
SNDL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.68%, which is quite good.
Looking at the last year, SNDL shows a small growth in Revenue. The Revenue has grown by 4.43% in the last year.
The Revenue has been growing by 70.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)16.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.59%
Revenue 1Y (TTM)4.43%
Revenue growth 3Y154.1%
Revenue growth 5Y70.65%
Sales Q2Q%5.35%
3.2 Future
SNDL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.75% yearly.
Based on estimates for the next years, SNDL will show a small growth in Revenue. The Revenue will grow by 3.37% on average per year.
EPS Next Y51.52%
EPS Next 2Y43.55%
EPS Next 3Y33.21%
EPS Next 5Y42.75%
Revenue Next Year4.28%
Revenue Next 2Y3.69%
Revenue Next 3Y3.05%
Revenue Next 5Y3.37%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SNDL. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 232.79, which means the current valuation is very expensive for SNDL.
66.49% of the companies in the same industry are more expensive than SNDL, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 23.56. SNDL is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 232.79 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SNDL is valued cheaper than 84.29% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SNDL indicates a rather cheap valuation: SNDL is cheaper than 90.05% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.62 | ||
| EV/EBITDA | 11.3 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SNDL does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as SNDL's earnings are expected to grow with 33.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.55%
EPS Next 3Y33.21%
5. Dividend
5.1 Amount
No dividends for SNDL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:SNDL (12/9/2025, 1:58:05 PM)
1.72
+0.04 (+2.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners23.02%
Inst Owner Change34.19%
Ins Owners4.34%
Ins Owner ChangeN/A
Market Cap442.73M
Revenue(TTM)951.58M
Net Income(TTM)-92.28M
Analysts82.5
Price Target5.71 (231.98%)
Short Float %0.65%
Short Ratio0.5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.83%
Min EPS beat(2)-83.95%
Max EPS beat(2)119.61%
EPS beat(4)3
Avg EPS beat(4)111%
Min EPS beat(4)-83.95%
Max EPS beat(4)345.1%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.86%
Min Revenue beat(2)0.07%
Max Revenue beat(2)3.66%
Revenue beat(4)3
Avg Revenue beat(4)-0.21%
Min Revenue beat(4)-6.38%
Max Revenue beat(4)3.66%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-19.99%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-166.67%
EPS NY rev (3m)-166.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.18%
Revenue NY rev (3m)-0.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 232.79 | ||
| P/S | 0.64 | ||
| P/FCF | 10.62 | ||
| P/OCF | 8.77 | ||
| P/B | 0.56 | ||
| P/tB | 0.67 | ||
| EV/EBITDA | 11.3 |
EPS(TTM)-0.02
EYN/A
EPS(NY)0.01
Fwd EY0.43%
FCF(TTM)0.16
FCFY9.42%
OCF(TTM)0.2
OCFY11.41%
SpS2.68
BVpS3.09
TBVpS2.58
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7% | ||
| ROE | -8.39% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 27.03% | ||
| FCFM | 6.05% |
ROA(3y)-13.41%
ROA(5y)-27.04%
ROE(3y)-16.09%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y38.61%
GM growth 5Y-0.23%
F-Score6
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 2.69 | ||
| Debt/EBITDA | 2.69 | ||
| Cap/Depr | 21.63% | ||
| Cap/Sales | 1.28% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 156.16% | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.04 | ||
| Quick Ratio | 3.54 | ||
| Altman-Z | 1.25 |
F-Score6
WACC8.11%
ROIC/WACCN/A
Cap/Depr(3y)18.2%
Cap/Depr(5y)23.85%
Cap/Sales(3y)1.2%
Cap/Sales(5y)3.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.59%
EPS Next Y51.52%
EPS Next 2Y43.55%
EPS Next 3Y33.21%
EPS Next 5Y42.75%
Revenue 1Y (TTM)4.43%
Revenue growth 3Y154.1%
Revenue growth 5Y70.65%
Sales Q2Q%5.35%
Revenue Next Year4.28%
Revenue Next 2Y3.69%
Revenue Next 3Y3.05%
Revenue Next 5Y3.37%
EBIT growth 1Y73.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year657.88%
EBIT Next 3Y150.28%
EBIT Next 5Y93%
FCF growth 1Y604.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4779.4%
OCF growth 3YN/A
OCF growth 5YN/A
SNDL INC / SNDL FAQ
Can you provide the ChartMill fundamental rating for SNDL INC?
ChartMill assigns a fundamental rating of 4 / 10 to SNDL.
What is the valuation status for SNDL stock?
ChartMill assigns a valuation rating of 4 / 10 to SNDL INC (SNDL). This can be considered as Fairly Valued.
What is the profitability of SNDL stock?
SNDL INC (SNDL) has a profitability rating of 2 / 10.
What is the financial health of SNDL INC (SNDL) stock?
The financial health rating of SNDL INC (SNDL) is 6 / 10.